Apexian

Apexian is a biotechnology company focused on developing novel compounds to treat cancer. Our lead drug candidate APX3330  targets the APE1/Ref-1 redox protein, a molecule found in many cancers, including tumors of the colon, lung, breast, pancreas and others. Our experienced team of research scientists and clinical specialists will commence studies of APX3330 for the treatment of cancer in 2017.